<DOC>
	<DOCNO>NCT00662506</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose cediranib see well work give together temozolomide radiation therapy treat patient newly diagnose glioblastoma . Cediranib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Drugs use chemotherapy , temozolomide , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving cediranib together temozolomide radiation therapy may kill tumor cell .</brief_summary>
	<brief_title>Cediranib , Temozolomide , Radiation Therapy Treating Patients With Newly Diagnosed Glioblastoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine safety profile optimal dose AZD2171 ( cediranib ) ( 15mg 20mg 30mg ) combination temozolomide radiation patient newly diagnose glioblastoma ( Phase Ib ) II . To determine median progression-free survival patient newly diagnose glioblastoma treat AZD2171 combination temozolomide radiation ( Phase II ) SECONDARY OBJECTIVES : I . To determine radiographic response proportion newly diagnose glioblastoma patient measurable disease . ( Phase II ) II . To determine median overall survival . ( Phase II ) III . To determine `` vascular normalization '' window newly diagnose glioblastoma patient application serial , non-invasive , MRI parameter . ( Phase II ) IV . To measure glucose metabolism change subset newly diagnose glioblastoma patient perform FDG PET study . ( Phase II ) V. Measurement circulate endothelial progenitor cell plasma level VEGF-A ; VEGF-B ; VEGF-C ; VEGF-D ; sVEGFR1 , sVEGFR2 , bFGF , PlGF , PDGF-AA ; PDGF-AB ; PDGF-BB ; SDF1α ; tumstatin ; thrombospondin-1 ; interleukin-8 ; collagen IV sICAM1 , sVCAM1 marker response AZD2171 newly diagnose glioblastoma patient . ( Phase II ) VI . Correlation treatment outcomes pre-AZD2171 tumor specimen respect cell proliferation , apoptosis , microvascular density ( MVD ) , basement membrane pericyte coverage , angiopoietin-1 -2 expression determine whether immunohistochemical analysis predictive response AZD2171 . ( Phase II ) OUTLINE : This phase I , dose-escalation study cediranib follow phase II study . Patients begin study treatment within 21-42 day craniotomy 14-21 day stereotactic biopsy . PHASE Ib : CHEMORADIOTHERAPY : Patients receive cediranib orally ( PO ) daily oral temozolomide daily 6 week . Within 2-6 hour dose , patient undergo concurrent intensity-modulated radiotherapy ( IMRT ) daily , 5 day week 6 week . Cediranib monotherapy : Patients receive cediranib PO daily 4 week ( week 7-10 ) . Cediranib temozolomide monthly therapy : Patients receive cediranib PO daily 24 week ( week 11-34 ) temozolomide daily , 5 day week week 11 , 15 , 19 , 23 , 27 , 31 . Cediranib monotherapy : Patients receive fixed-dose cediranib daily 24 week ( week 35-58 ) . PHASE II : CHEMORADIOTHERAPY : Patients receive cediranib PO recommend phase II dose determine phase Ib , temozolomide PO , undergo concurrent IMRT phase Ib ( week 1-6 ) . Cediranib monotherapy : Patients receive cediranib PO ( recommend phase II dose determine phase Ib ) daily 4 week ( week 7-10 ) . Cediranib temozolomide monthly therapy : Patients receive cediranib PO ( recommend phase II dose determine phase Ib ) daily 24 week ( week 11-34 ) temozolomide daily , 5 day week week 11 , 15 , 19 , 23 , 27 , 31 . Cediranib monotherapy : Patients receive fixed-dose cediranib daily 24 week ( week 35-58 ) . Patients undergo blood urine sample collection baseline periodically study . Blood sample measure tumstatin , well well establish biomarkers , include VEGF-A , -D , sVEGFR1 , sVEGFR2 , sICAM1 , sVCAM1 , PlGF , PDGF-AA , PDGF-AB , PDGF-BB , thrombospondin-1 , IL-8 electrochemiluminescence detection . Circulating endothelial cell ( CEC ) assay evaluated ass kinetics CECs progenitor cell prior antiangiogenic therapy cediranib chemoradiotherapy . Urine sample collect proteomic analysis evaluate serial change growth factor VEGF PlGF matrix metalloproteinases response treatment cediranib . Archival tumor tissue collect analysis tumor microvascular density , basement membrane pericyte coverage , angiopoietin-1 -2 expression , tumor cell proliferation , apoptosis immunostaining method immunoenzyme technique . Patients also undergo dynamic contrast enhance ( DCE ) -MRI T2-weighted perfusion-weighted MRI baseline periodically study monitor antiangiogenic effect tumor vasculature parameter reflect tumor perfusion permeability ; diffusion tensor image measure degree water diffusion fractional anisotropy . A subset patient undergo fludeoxyglucose F 18 positron emission tomography ( FDG-PET ) periodically monitor antiangiogenic effect glucose utilization . After completion study treatment , patient follow periodically 1 year .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>Histologically confirm glioblastoma Newly diagnose disease Scheduled receive standard postsurgical ( i.e. , biopsy resection ) temozolomide radiotherapy Must residual , contrastenhancing tumor ( ≥ 1 centimeter ≥ 1 dimension ) Patients must maintain stable corticosteroid regimen 5 day prior baseline scan 5 day prior first vascular MRI ; dose steroid remain baseline vascular MRIs Archival tumor tissue available molecular analysis No intratumoral hemorrhage peritumoral hemorrhage MRI Karnofsky performance status 60100 % Leukocytes ≥ 3,000/mcl Absolute neutrophil count ≥ 1,500/mcL Platelet count ≥ 100,000/mcL Hemoglobin ≥ 8 g/dL Total bilirubin normal AST/ALT ≤ 2.5 time upper limit normal Creatinine normal OR creatinine clearance ≥ 60 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Proteinuria ≤ 1+ two consecutive dipstick ≥ 7 day apart Minimental status examination score ≥ 15 Must able tolerate MRI must consent participate additional Vascular Imaging Procedures per protocol CT scan substitute MRI Mean QTc ≤ 500 msec ( Bazett 's correction ) electrocardiogram No concurrent malignancy except curatively treat basal cell squamous cell carcinoma skin cancer carcinoma situ cervix breast Patients prior malignancy must diseasefree ≥ 5 year No history familial long QT syndrome significant ECG abnormality No history allergic reaction attribute compound similar chemical biologic composition cediranib No uncontrolled intercurrent illness include , limited , follow : Hypertension ( e.g. , blood pressure &gt; 140/90 mm Hg ) Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness/social situation would preclude study compliance No known coagulopathy increase risk bleed No history clinically significant hemorrhage past No New York Heart Association class IIIIV heart disease No condition require concurrent drug biologics proarrhythmic potential No concurrent chemotherapy agent , investigational agent , biologic therapy No prior chemotherapy , radiotherapy , experimental therapy disease No prior IV bevacizumab medical condition No prior carmustine implant ( Gliadel Wafer ) No prior brachytherapy radiosurgery disease More 30 day since prior concurrent investigational agent participation investigational therapeutic trial At least 2 week since prior concurrent enzymeinducing antiepileptic drug ( EIAEDs ) Concurrent nonEIAEDs allow No concurrent CYP450inducing anticonvulsant No concurrent anticoagulant ( e.g. , dalteparin , warfarin , lowmolecular weight heparin ) If patient require warfarin anticoagulant ( e.g. , lowmolecular weight heparin ) study , patient may continue treatment No concurrent combination antiretroviral therapy HIVpositive patient No concurrent VEGF inhibitors No concurrent pentamidine No concurrent herbal nontraditional medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>